The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Agenus; Asher Biotherapeutics; AstraZeneca; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; GlaxoSmithKline; Idera; Merck; Novartis; Oncorena; PACT Pharma; Pfizer; Pliant; Pyxis; Sanofi; Scholar Rock; Simcha Therapeutics; Surface Oncology; Takeda; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Pooja Ghatalia
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)
 
Jaime R. Merchan
Consulting or Advisory Role - Merck
Research Funding - BioNTech (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); IMUGENE (Inst); Merck (Inst); Peloton Therapeutics (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Seattle Genetics/Astellas (Inst); Sillajen (Inst); Tizona Therapeutics, Inc. (Inst); Tocagen (Inst); Trishula Therapeutics (Inst); Vyriad (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Saby George
Consulting or Advisory Role - AstraZeneca; AVEO; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Merck; Novartis; Pfizer; QED Therapeutics; Sanofi; Seattle Genetics/Astellas
Research Funding - Agensys (Inst); Aravive (Inst); Aveo (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Sanofi
 
John Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); bioNTech (Inst); Bristol-Myers Squibb (Inst); CureVac; Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Novartis (Inst); Pfizer (Inst); POEM Health (Inst); Roche/Genentech (Inst); Sanofi (Inst); T-Knife (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Asher Biotherapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Howard Gurney
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Merck Serono
 
Rahul Ravilla
Consulting or Advisory Role - Seagen
Speakers' Bureau - Bristol-Myers Squibb; Exelixis; Janssen
 
Astrid Aplonia Maria Van Der Veldt
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Novartis; Roche; Roche
 
Benoit Beuselinck
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; MSD; Pfizer
Research Funding - BMS GmbH & Co. KG
Expert Testimony - MSD
 
Ilya Pokataev
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Eisai; Merck; Novartis; Pfizer; Pierre Fabre; Roche; Swixx BioPharma
 
Britt Suelmann
No Relationships to Disclose
 
Mark H. Tuthill
Honoraria - Eisai; Eisai
Consulting or Advisory Role - Gilead Sciences; Novartis; Oxford VacMedix; Roche; Seagen
Speakers' Bureau - Bayer; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Seagen
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Merck; Novartis
 
Daniel A. Vaena
Honoraria - HMP; OncLive; OneOncology; Total Health Conferencing
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Cardinal Health; Curio/Vaniam Group; DAVA Pharmaceuticals; Eisai; EMD Serono; Exelixis; Gilead Sciences; IntrinsiQ; Janssen; MJH Life Sciences; Sanofi; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Exelixis (Inst); Merck (Inst); OBI Pharma (Inst); Roche/Genentech (Inst); Seagen (Inst); Tallac Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Tempus
 
Flora Zagouri
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD; Novartis; Pfizer Hellas; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
 
Jianxin Lin
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yanfang Liu
Employment - Bristol-Myers Squibb; Merck
 
James Brugarolas
Consulting or Advisory Role - Exelixis; Johnson & Johnson; Telix Pharmaceuticals
Patents, Royalties, Other Intellectual Property - U.S. Application Number: 17/153,128 “PET RADIOPHARMACEUTICALS FOR NON-INVASIVE EVALUATION OF HIF-2alpha” (Inst); U.S. Application Number: 17/206,895 “BIOMARKERS OF RESPONSE TO HIF-2alpha INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF” (Inst); U.S. Patent: US 11,576,889 B2 "METHODS OF IDENTIFYING AND TREATING PATIENTS WITH HIF-2 INHIBITOR RESISTANCE" (Inst)
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer